Welcome to our dedicated page for International Flavors&Fragranc news (Ticker: IFF), a resource for investors and traders seeking the latest updates and insights on International Flavors&Fragranc stock.
International Flavors & Fragrances Inc. (IFF) (NYSE: IFF) generates a steady flow of news that reflects its role as a global leader in flavors, fragrances, food ingredients, health and biosciences. This news page aggregates company announcements, press releases and related coverage so readers can follow how IFF’s strategies, operations and governance evolve over time.
IFF’s news often highlights developments across its core segments—Taste, Health & Biosciences, Scent and Food Ingredients. Examples include updates on segment performance from quarterly earnings releases, commentary on market dynamics within these segments and information on productivity and margin initiatives. Investors and analysts can use these items to understand how the company’s segment-level trends contribute to overall performance.
Operational and technology-focused announcements are another key news category for IFF. Recent releases describe the implementation of the Colibri smart dosing robot at its Scent and Taste production plant in Chin Bee, Singapore, which is used to produce fragrance sample batches on demand, and the installation of a green hydrogen production facility at its Benicarló, Spain site to support sustainable fragrance ingredient manufacturing. News items also cover plans for new facilities, such as a scent creative center in Mumbai, India, designed to enhance fragrance innovation in that market.
Corporate governance, capital allocation and strategic partnerships feature prominently in IFF’s news flow. The company reports on board appointments, changes in committee assignments and amendments to its bylaws. It also announces dividends, share repurchase authorizations and collaborations, such as its strategic collaboration with BASF to develop next-generation enzyme technologies and biobased polymers. Bookmark this page to access a consolidated view of IFF’s latest publicly released information, from financial results to sustainability initiatives and board-level decisions.
IFF (NYSE: IFF) reported its Q4 and full year 2024 financial results, with full-year sales reaching $11.48 billion, flat compared to the previous year. On a comparable basis, currency neutral sales increased 6%, driven by double-digit performance in Scent and high-single digit growth in Health & Biosciences.
Full-year income before taxes was $278 million, with adjusted operating EBITDA of $2.21 billion. The company achieved earnings per share of $0.95, while adjusted EPS excluding amortization was $4.31. Cash flow from operations totaled $1,070 million.
For 2025, IFF expects sales between $10.6 billion to $10.9 billion and adjusted operating EBITDA of $2-2.15 billion. The guidance includes six months of Pharma Solutions results, assuming its divestiture closes on June 30, 2025. Comparable currency neutral sales growth is projected at 1-4%, with volume growth across all businesses.
IFF (NYSE: IFF) has launched its redesigned corporate website, www.iff.com, featuring significant improvements in scale, performance, and digital experience. The new site showcases IFF's leadership and portfolio value across its markets through improved navigation, fresh content, and enhanced lead-generation tools.
Key features include a comprehensive media center, an expanded sustainability hub, and sections dedicated to careers, history, insights, and science. The responsive design enables customized user journeys and better access to business-specific content. The revamp aims to increase brand recognition, strengthen customer relationships, and attract talent.
The website redesign reflects IFF's brand identity as a global leader in flavors, fragrances, food ingredients, health and biosciences, emphasizing the company's focus on delivering sustainable innovations through science, creativity, and heart.
IFF (NYSE: IFF) has launched ScentChat™, an AI-powered instant messaging application designed to revolutionize fragrance creation through real-time consumer feedback. The app integrates with popular messaging platforms like WhatsApp and Facebook Messenger, enabling direct communication between consumers and fragrance creators.
Using advanced semantic AI and Natural Language Processing (NLP), ScentChat™ analyzes consumer feedback and generates instant insight reports that help perfumers make informed decisions about ingredients. The tool addresses traditional barriers in consumer research by offering a cost-effective, accessible, and scalable solution for gathering authentic sensory feedback.
The application represents a significant advancement in applying generative AI to perfumery, combining human experience with technology to streamline the fragrance creation process. It creates a collaborative environment between consumers and creators while making innovation more efficient and impactful.
IFF (NYSE:IFF) has announced its schedule for upcoming investor events in February 2025. The company will release its fourth quarter and full year 2024 earnings results after market close on February 18, 2025. A live webcast with management to discuss results and outlook will follow on February 19, 2025, at 9:00 a.m. ET.
Additionally, IFF management will present at the Consumer Analyst Group of New York (CAGNY) conference on February 20, 2025, at 1:00 PM ET. Both events will be accessible through webcasts on the company's investor relations website at ir.iff.com, with replay options available for those unable to attend live.
IFF (NYSE:IFF) has launched Enviva® DUO, a new direct-fed microbial (DFM) solution for poultry production. The product features a blend of two non-spore forming bacterial strains designed to support beneficial gut bacteria growth and promote optimal bird performance through waterline application.
The solution targets specific houses or farms through direct dosing, ensuring challenged birds receive microbiome-boosting benefits even during decreased feed intake. Scientific research validates Enviva® DUO's ability to restore bird microbiome and stabilize intestinal environment, while its stable formulation ensures uniform distribution without settling in water systems.
The product is currently available in the U.S., India, and Pakistan, with planned expansion to other markets pending regulatory approvals.
IFF Pharma Solutions has been awarded the 2024 Pharmaceutical Technology Excellence Award in the Brand Leadership category for its 'Timing is Everything' campaign. The campaign showcases IFF's new controlled release platform for oral drug delivery, implementing a three-pronged approach including social media teasers, video content, and a microsite.
The platform features key products including METHOCEL™, ETHOCEL™, and POLYOX™, focusing on controlled release polymers in pharmaceutical formulations. The campaign creates a comprehensive thought leadership platform providing educational resources such as white papers, webinars, and articles about controlled release of active ingredients.
The Pharmaceutical Technology Excellence Awards, powered by GlobalData's business intelligence, recognizes significant achievements and innovations in the pharmaceutical industry. The award acknowledges the campaign's strategic marketing tactics, creativity, and leadership in building an integrated thought leadership platform.
IFF (NYSE: IFF) has launched the China Scent Exploration Program, a consumer learning initiative aimed at creating unique fragrances for the Chinese market. This program leverages IFF's long-standing regional expertise, which began in 1981, and combines artificial intelligence with deep cultural insights.
According to Ana Paula Mendonça, President of Scent at IFF, the Chinese fragrance market offers significant opportunities. The program targets a market that includes fine fragrance ($2.15 billion), beauty and personal care ($77.35 billion), and home care ($18 billion).
The program is structured around four strategic pillars:
- Historical and cultural imprint: Analyzes traditional fragrance ingredients for modern use.
- Sensorial influences: Researches cultural and botanical references to develop authentic scent profiles.
- Consumer insights: Surveys 10,000 people across various cities and generations, monitoring social media trends.
- Artificial intelligence: Translates insights into precise fragrance creation guidelines.
Arnaud Montet, VP of Global Human & Consumer Insights, stated that this large-scale research enables targeted fragrance development, reducing time and costs.
The initiative addresses key market challenges, such as evolving consumer preferences and the need for culturally authentic fragrances, enhancing IFF's ability to guide strategic decisions and create tailored scents for the Chinese market.
IFF announced significant changes to its Board of Directors, effective through 2025. Kevin O'Byrne, current board member and Centrica plc chair, will become Board Chair at the 2025 Annual Shareholder Meeting, succeeding Roger W. Ferguson, Jr. who will not seek reelection after 14 years of service.
Three new directors - Cynthia Jamison, Dr. Mehmood Khan, and Vincent Intrieri - will join effective January 1, 2025. Intrieri's appointment comes at Icahn Capital LP's request, replacing Gary Hu. Additionally, Christina Gold and John Davidson will not seek reelection in 2025, resulting in a ten-member board structure.
IFF Pharma Solutions has launched AnswerCenter, a new web-based customer experience platform designed to enhance user experience and provide comprehensive support. The platform features an intuitive interface allowing customers to browse products by market, technology, or segment, with advanced filtering options for excipients and ingredients across pharmaceuticals, biologics, dietary supplements, and other sectors.
The platform provides access to detailed technical information, regulatory guidelines, and documentation related to product brands, quality, technical data sheets, supply chain, and regulatory support. AnswerCenter represents a key component of IFF's digital transformation strategy, aiming to streamline customer access to information while maintaining personal customer relationships.
IFF has announced the appointment of Michael DeVeau as Executive Vice President and Chief Financial Officer, effective January 1, 2025. DeVeau, currently Senior Vice President of Corporate Finance and Investor Relations, will succeed Glenn Richter, who will retire at the end of 2024.
DeVeau brings 15 years of experience at IFF, having served in multiple senior finance leadership roles including Divisional CFO of Scent and Chief Strategy Officer. In his current role, he oversees corporate and divisional financial planning and analysis, corporate strategy, and investor relations. Prior to IFF, he held positions at PepsiCo and started his career as an equity research analyst at Citigroup Investment Research.